Impact of vitamin D3 supplementation on motor functionality and the immune response in Parkinson's disease patients with vitamin D deficiency.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc in the context of parkinson's disease.

Parkinson's disease (PD) patients frequently exhibit vitamin D deficiency and an imbalance in T helper 17 (Th17) and regulatory T (Treg) cells, which may contribute to disease pathogenesis.

This randomized controlled trial investigated peripheral blood levels of vitamin D, Treg, and Th17 cells in PD patients, examined their associations with clinical outcomes, and assessed vitamin D3 supplementation's effects on immunological and motor functions.

Who Took Part

According to the abstract, 51 patients were involved.

By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.

In this randomized, double-blind, placebo-controlled trial, 51 PD patients and 50 healthy controls (HCs) were enrolled.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

The patients were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

Neither the patients nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.

Some patients received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

Serum 25(OH)D3 levels were measured by electrochemiluminescence, and Th17/Treg cells were analyzed by flow cytometry.

What Was Measured

This randomized controlled trial investigated peripheral blood levels of vitamin D, Treg, and Th17 cells in PD patients, examined their associations with clinical outcomes, and assessed vitamin D3 supplementation's effects on immunological and motor functions.

Topics PubMed links to this paper include Parkinson Disease, Cholecalciferol, Vitamin D Deficiency, Th17 Cells, T-Lymphocytes, Regulatory, Dietary Supplements and Vitamin D.

Author keywords: Parkinson’s disease and Treg.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 51 patients in people with parkinson's disease.

The publication is from 2025 (Scientific reports), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, Parkinson's disease research.